Ginkgo Bioworks Holdings Inc. (DNA) closed at $7.06, up 1 percent, outperforming the S&P 500's 0.45 percent loss and Nasdaq's 0.01 percent decline. Shares have gained 7.04 percent over the past month, beating the Medical sector's 0.29 percent loss.
The headline numbers look brutal. Analysts expect Ginkgo to report earnings of minus $0.58 per share for Q3—a 60 percent improvement year-over-year, though still deeply negative. Revenue consensus: $20.5 million, down 47 percent from the prior-year quarter. For the full year, the Street projects minus $3.2 per share in earnings and $82.2 million in revenue, a 52 percent decline.
Here is what matters: Ginkgo is a platform biotech in disciplined cost-cutting mode. The company is shrinking its revenue footprint by exiting unprofitable programs while doubling down on autonomous lab technology—its genuine differentiator. Unit economics on the remaining revenue are improving, which explains why earnings are contracting less sharply than the top line.
The Zacks Rank sits at #3 (Hold), with the consensus EPS estimate unchanged over the past month. The stock's Medical—Biomedical and Genetics industry ranks 165th out of 250-plus, placing it in the bottom third. That discount is justified for now.
For investors, the trade hinges on execution of autonomous lab commercialization over the next two quarters. If Ginkgo can stabilize revenue while maintaining cost discipline, it has a path to cash flow positive. If revenue accelerates before that inflection, DNA could be underpriced here. Current holders should monitor Q3 guidance for autonomous lab pipeline signals; new money should wait for evidence of revenue stabilization.
